siRNA
-
53.6亿美元！舶望制药siRNA疗法再出海
融资的机会来了！~ 多家知名VC公司寻找优质投资标的， 感兴趣的管线包括： （1）针对实体瘤的创新性TCE、（2）新靶点/新核素的创新性核药、（3）Abeta双靶点等CNS创新…
-
【IND-enabling】siRNA Therapeutics Targeting AGT for Hypertension 【Product for Licensing】
If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap. Many thanks!~
-
siRNA Therapeutics Targeting PD-L1 for HBV 【Product for Licensing】
If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap. Many thanks!~
-
siRNA Therapeutics Targeting APP for Alzheimer’s Disease (AD) 【Product for Licensing】
If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap. Many thanks!~
-
siRNA Therapeutics Targeting Nav1.7 for Chronic Pain 【Product for Licensing】
If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap
-
siRNA Therapeutics Targeting INHBE and another target 【Product for Licensing】
If you are interested in this asset or need more information, please contact DrugTimes BD Team at BD@drugtimes.cn or visit our website at https://www.drugtimes.cn
-
ALK7-targeting siRNA Therapeutics for fat reduction without muscle loss 【Product for Licensing】
If you are interested in this asset or need more information, please contact DrugTimes BD Team at BD@drugtimes.cn or visit our website at https://www.drugtimes.cn
-
A PD-L1 siRNA that Can Boost Immune Response for CHB Functional Cure 【Product for Licensing】
If you are interested in this product, please contact us at BD@drugtimes.cn. Many thanks!
-
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
Congratulations to Alnylam and patients who may benefit from this exciting progress!
